The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer

Randall J. Kimple; Suzanne Russo; Arta M Monjazeb; A. William Blackstock

doi:10.1586/era.12.18

The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer

Randall J. Kimple, Suzanne Russo, Arta M Monjazeb, A. William Blackstock

Radiation Oncology

Research output: Contribution to journal › Article

7 Scopus citations

Abstract

Conflicting data and substantial controversy exist regarding optimal adjuvant treatment for those patients with resectable or potentially resectable adenocarcinoma of the pancreas. Despite improvements in short-term surgical outcomes, the use of newer chemotherapeutic agents, development of targeted agents and more precise delivery of radiation, the 5-year survival rates for early-stage patients remains less than 25%. This article critically reviews the existing data for various adjuvant treatment approaches for patients with surgically resectable pancreatic cancer. Our review confirms that despite several randomized clinical trials, the optimal adjuvant treatment approach for these patients remains unclear.

Original language	English (US)
Pages (from-to)	469-480
Number of pages	12
Journal	Expert Review of Anticancer Therapy
Volume	12
Issue number	4
DOIs	https://doi.org/10.1586/era.12.18
State	Published - Apr 2012

Fingerprint

Keywords

biological markers
combined modality therapy
molecular targets
neoadjuvant
pancreatic adenocarcinoma
radiotherapy

ASJC Scopus subject areas

Pharmacology (medical)
Oncology

Cite this

Kimple, R. J., Russo, S., Monjazeb, A. M., & Blackstock, A. W. (2012). The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Review of Anticancer Therapy, 12(4), 469-480. https://doi.org/10.1586/era.12.18

@article{ed52d968d9ae413eb303da4d9ab04212,

title = "The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer",

abstract = "Conflicting data and substantial controversy exist regarding optimal adjuvant treatment for those patients with resectable or potentially resectable adenocarcinoma of the pancreas. Despite improvements in short-term surgical outcomes, the use of newer chemotherapeutic agents, development of targeted agents and more precise delivery of radiation, the 5-year survival rates for early-stage patients remains less than 25%. This article critically reviews the existing data for various adjuvant treatment approaches for patients with surgically resectable pancreatic cancer. Our review confirms that despite several randomized clinical trials, the optimal adjuvant treatment approach for these patients remains unclear.",

keywords = "biological markers, combined modality therapy, molecular targets, neoadjuvant, pancreatic adenocarcinoma, radiotherapy",

author = "Kimple, {Randall J.} and Suzanne Russo and Monjazeb, {Arta M} and Blackstock, {A. William}",

year = "2012",

month = apr

doi = "10.1586/era.12.18",

language = "English (US)",

volume = "12",

pages = "469--480",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "4",

}

TY - JOUR

T1 - The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer

AU - Kimple, Randall J.

AU - Russo, Suzanne

AU - Monjazeb, Arta M

AU - Blackstock, A. William

PY - 2012/4

Y1 - 2012/4

N2 - Conflicting data and substantial controversy exist regarding optimal adjuvant treatment for those patients with resectable or potentially resectable adenocarcinoma of the pancreas. Despite improvements in short-term surgical outcomes, the use of newer chemotherapeutic agents, development of targeted agents and more precise delivery of radiation, the 5-year survival rates for early-stage patients remains less than 25%. This article critically reviews the existing data for various adjuvant treatment approaches for patients with surgically resectable pancreatic cancer. Our review confirms that despite several randomized clinical trials, the optimal adjuvant treatment approach for these patients remains unclear.

AB - Conflicting data and substantial controversy exist regarding optimal adjuvant treatment for those patients with resectable or potentially resectable adenocarcinoma of the pancreas. Despite improvements in short-term surgical outcomes, the use of newer chemotherapeutic agents, development of targeted agents and more precise delivery of radiation, the 5-year survival rates for early-stage patients remains less than 25%. This article critically reviews the existing data for various adjuvant treatment approaches for patients with surgically resectable pancreatic cancer. Our review confirms that despite several randomized clinical trials, the optimal adjuvant treatment approach for these patients remains unclear.

KW - biological markers

KW - combined modality therapy

KW - molecular targets

KW - neoadjuvant

KW - pancreatic adenocarcinoma

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84859795721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859795721&partnerID=8YFLogxK

U2 - 10.1586/era.12.18

DO - 10.1586/era.12.18

M3 - Article

C2 - 22500684

AN - SCOPUS:84859795721

VL - 12

SP - 469

EP - 480

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 4

ER -

Access to Document

10.1586/era.12.18